Safety of stem cells for chronic lung transplant rejection
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether a single dose of stem cells given through a bronchoscope is safe for people whose lungs are failing after a transplant. It may help those with a condition called bronchiolitis obliterans syndrome (BOS), a type of chronic rejection that makes it harder to breathe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have had a single or double lung transplant
- You have been diagnosed with chronic rejection (BOS) in the last 6 months, shown by a drop in lung function
- You do not have an active infection or untreated acute rejection
- You are not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if stem cells can help premature babies with severe lung disease (bronchopulmonary dysplasia). It is for very small, early-born babies who still need a breathing machine between 5 and 14 days after birth.
This study follows lung health after a stem cell transplant from a donor, to understand and manage chronic graft-versus-host disease (a condition where donor cells attack the body). It may help people who are about to have their first donor transplant.
This early trial tests if airway basal stem cells can help children with a serious lung condition called bronchiolitis obliterans. It aims to improve lung function and reduce the need for oxygen or breathing support.
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
This study tests whether the drug LAM-001 can help people who have developed a condition called bronchiolitis obliterans syndrome (BOS) after a double lung transplant. BOS causes a slow decline in lung function, and this trial aims to see if LAM-001 can slow or stop that decline.
Hear when a new Chronic Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.